Document Detail


Elimination of malignant clonogenic breast cancer cells from human bone marrow.
MedLine Citation:
PMID:  2663144     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Autologous bone marrow transplantation is a promising approach to the treatment of breast cancer but is at present limited to patients without bone marrow metastases. To eliminate malignant clonogenic breast cancer cells from normal human bone marrow, immunomagnetic separation has been combined with chemoseparation using 4-hydroperoxycyclophosphamide. Breast cancer cell lines have been mixed with a 10-fold excess of irradiated human bone marrow from normal donors. Mixtures have been incubated with a combination of five different monoclonal antibodies which bind to epithelial cell surface antigens of Mr 42,000, 55,000, 72,000, 200,000, and greater than 200,000. Antiglobulin coated microspheres which contained magnetite were added, and tumor cells were trapped in a magnetic field. Elimination of tumor cells from the decanted marrow was measured in a limiting dilution assay. Two treatments with antibody and microspheres permitted elimination of 2-4 logs of clonogenic breast cancer cells, depending upon the cell line studied. Similar treatment of nonirradiated normal marrow failed to affect levels of colony forming units-granulocyte-macrophage significantly. Use of immunomagnetic purging in combination with 4-hydroperoxycyclophosphamide eliminated up to 5 logs of tumor cells but reduced the recovery of colony forming units-granulocyte-macrophage. If prompt engraftment is observed following reinfusion of similarly treated marrow in phase I trials, these techniques should permit extension of autologous bone marrow transplantation to a larger population of breast cancer patients.
Authors:
I C Anderson; E J Shpall; D S Leslie; K Nustad; J Ugelstad; W P Peters; R C Bast
Related Documents :
19083584 - Complication after breast implantation in poland syndrome.
17657174 - A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patien...
12602924 - Elevated serum periostin levels in patients with bone metastases from breast but not lu...
18791864 - Evaluation of a rt-pcr based routine screening tool for the detection of disseminated e...
17004114 - Bad expression predicts outcome in patients treated with tamoxifen.
21492444 - Estrogen receptor β represses akt signaling in breast cancer cells via downregulation ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  49     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1989-08-23     Completed Date:  1989-08-23     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  4659-64     Citation Subset:  IM    
Affiliation:
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / diagnostic use
Bone Marrow / pathology*
Bone Marrow Transplantation
Breast Neoplasms / drug therapy,  pathology*,  therapy
Cell Line
Cell Separation / methods*
Colony-Forming Units Assay / methods*
Female
Humans
Magnetics
Tumor Stem Cell Assay / methods*
Grant Support
ID/Acronym/Agency:
5-R01-CA 39930/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma.
Next Document:  United States experience and perspectives with trazodone.